SMTL ID : 3oki.2 (1 other biounit)

Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 2.00 Å

Oligo State

hetero-1-1-mer

Ligands

1 x OKI: (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2-dicyclohexylethanamide(Non-covalent)

OKI.1: 17 residues within 4Å: Chain A: I.30, I.34, N.44, L.48, M.51, H.55, M.89, F.90, R.92, S.93, I.96, F.97, I.113, S.116, M.126, Y.130, M.211 13 PLIP interactions: 13 interactions with chain A Hydrophobic interactions: A:I.30, A:I.34, A:N.44, A:L.48, A:H.55, A:F.90, A:R.92, A:I.96, A:I.96, A:I.113, A:Y.130 Hydrogen bonds: A:S.93, A:S.93

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Richter, H.G.F. et al., Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg.Med.Chem.Lett. (2010)

Release Date

2010-12-29

Peptides

Bile acid receptor: A
peptide of Nuclear receptor coactivator 1: B

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
C

B
D

Bile acid receptor

peptide of Nuclear receptor coactivator 1

Related Entries With Identical Sequence